Anna Feliu

2.9k total citations · 1 hit paper
50 papers, 2.0k citations indexed

About

Anna Feliu is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Anna Feliu has authored 50 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Physiology. Recurrent topics in Anna Feliu's work include Chronic Obstructive Pulmonary Disease (COPD) Research (11 papers), Hepatitis C virus research (10 papers) and Liver Disease Diagnosis and Treatment (8 papers). Anna Feliu is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (11 papers), Hepatitis C virus research (10 papers) and Liver Disease Diagnosis and Treatment (8 papers). Anna Feliu collaborates with scholars based in Spain, United Kingdom and United States. Anna Feliu's co-authors include Marc Miravitlles, Montserrat Garcı́a-Retortillo, Xavier Forns, Miquel Navasa, Antoni Rimola, Juan Rodés, Josep Costa, Eduardo Moitinho, Juan Carlos García‐Valdecasas and Jordi Vilà and has published in prestigious journals such as PLoS ONE, Hepatology and Scientific Reports.

In The Last Decade

Anna Feliu

48 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Understanding the impact of symptoms on the burden of COPD

2017 295 citations Anna Feliu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Feliu Spain	20	914	875	538	308	201	50	2.0k
Muriel Vray France	26	799 0.9×	519 0.6×	73 0.1×	58 0.2×	110 0.5×	96	2.2k
Seng‐Kee Chuah Taiwan	30	490 0.5×	313 0.4×	733 1.4×	124 0.4×	72 0.4×	179	3.1k
I Mura Italy	20	360 0.4×	73 0.1×	183 0.3×	70 0.2×	87 0.4×	60	1.1k
J. Gray United Kingdom	22	563 0.6×	172 0.2×	89 0.2×	33 0.1×	65 0.3×	78	1.7k
Matan J. Cohen Israel	21	271 0.3×	78 0.1×	141 0.3×	54 0.2×	176 0.9×	99	1.3k
Jeff Powis Canada	23	929 1.0×	321 0.4×	130 0.2×	59 0.2×	39 0.2×	82	1.6k
Kathleen A. Steger United States	19	624 0.7×	46 0.1×	440 0.8×	118 0.4×	101 0.5×	29	1.7k
Patricia Pavèse France	24	644 0.7×	69 0.1×	90 0.2×	101 0.3×	63 0.3×	113	1.6k
Jailson B. Correia Brazil	23	527 0.6×	242 0.3×	268 0.5×	59 0.2×	15 0.1×	54	1.6k
Thomas Ward United States	23	659 0.7×	276 0.3×	66 0.1×	28 0.1×	61 0.3×	61	1.5k

Countries citing papers authored by Anna Feliu

Since Specialization

Citations

This map shows the geographic impact of Anna Feliu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Feliu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Feliu more than expected).

Fields of papers citing papers by Anna Feliu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Feliu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Feliu. The network helps show where Anna Feliu may publish in the future.

Co-authorship network of co-authors of Anna Feliu

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Feliu. A scholar is included among the top collaborators of Anna Feliu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Feliu. Anna Feliu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guardiola, Josep M., Jesús Ruiz Ramos, Anna Feliu, et al.. (2024). Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis. Medicina Clínica (English Edition). 163(8). 391–396.

Feliu, Anna, et al.. (2024). Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?. Journal of Clinical Medicine. 13(8). 2355–2355. 2 indexed citations

Llirós, Marc, Robert Carreras‐Torres, Anna Feliu, et al.. (2024). Impact of bread diet on intestinal dysbiosis and irritable bowel syndrome symptoms in quiescent ulcerative colitis: A pilot study. PLoS ONE. 19(2). e0297836–e0297836. 5 indexed citations

Fort, Esther, María Ortiz, Anna Feliu, et al.. (2024). Metagenomic Study Reveals Phage–Bacterial Interactome Dynamics in Gut and Oral Microbiota in Pancreatic Diseases. International Journal of Molecular Sciences. 25(20). 10988–10988. 1 indexed citations

Ramos, Jesús Ruiz, et al.. (2024). Reacciones adversas a inhibidores de quinasa Janus: estudio de su incidencia y de factores predictivos en los pacientes con artritis reumatoide. Medicina Clínica. 163(8). 391–396. 1 indexed citations

Gich, Ignasi, Cèsar Díaz‐Torné, Hye Sang Park, et al.. (2024). Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Scientific Reports. 14(1). 172–172. 19 indexed citations

Díaz‐Torné, Cèsar, et al.. (2024). Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis. Medicina. 60(3). 360–360. 5 indexed citations

Oriol, Albert, et al.. (2023). Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study. Cancers. 15(22). 5338–5338. 1 indexed citations

Pontes, Caridad, et al.. (2022). HPR98 Availability and Reimbursement of Multiple Myeloma Drug Regimens in Spain. Value in Health. 25(12). S250–S250. 1 indexed citations

10.

Mirabet, Sònia, Eulàlia Roig, Laura López, et al.. (2020). Interdisciplinary Mobile Health Model to Improve Clinical Care After Heart Transplantation: Implementation Strategy Study. JMIR Cardio. 4(1). e19065–e19065. 7 indexed citations

11.

Roig, Eulàlia, Sònia Mirabet, Irene Conejo, et al.. (2020). A Mobile App (mHeart) to Detect Medication Nonadherence in the Heart Transplant Population: Validation Study. JMIR mhealth and uhealth. 8(2). e15957–e15957. 17 indexed citations

12.

D’Urzo, Anthony, Dave Singh, James F. Donohue, et al.. (2019). Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. International Journal of COPD. Volume 14. 479–491. 6 indexed citations

13.

Suárez-Cuartín, Guillermo, Jordi Giner, José Luís Merino, et al.. (2018). Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis. Respiratory Medicine. 136. 111–117. 18 indexed citations

14.

Cantó, Elisabet, Emma Roca, Lídia Perea, et al.. (2018). Salivary immunity and lower respiratory tract infections in non-elite marathon runners. PLoS ONE. 13(11). e0206059–e0206059. 16 indexed citations

15.

Rodrigo‐Troyano, Ana, Pedro J. Marcos, Elena Laserna, et al.. (2018). Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study. Respiration. 96(5). 417–424. 39 indexed citations

16.

Garín, Noé, Beatriz Zurita, César Velasco, et al.. (2017). Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study. BMJ Open. 7(1). e014105–e014105. 33 indexed citations

17.

Garín, Noé, César Velasco, Belén López, et al.. (2015). Recreational drug use among individuals living with HIV in Europe: review of the prevalence, comparison with the general population and HIV guidelines recommendations. Frontiers in Microbiology. 6. 1229–1229. 34 indexed citations

18.

Vestbo, Jørgen, et al.. (2010). Onset of Effect of Aclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD. COPD Journal of Chronic Obstructive Pulmonary Disease. 7(5). 331–336. 25 indexed citations

19.

Fuhr, Rainard, H Magnussen, Anna Feliu, et al.. (2010). Efficacy and Safety of Twice-Daily Aclidinium Bromide 400 μ g Compared With Placebo and Tiotropium 18 μ g QD in Moderate to Severe COPD Patients. CHEST Journal. 138(4). 465A–465A. 3 indexed citations

20.

Feliu, Anna, J.A. Carrión, Anna Massaguer, et al.. (2006). Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis. 13(8). 544–551. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact